NervGen Pharma (NASDAQ:NGEN) Rating Increased to Hold at Zacks Research

NervGen Pharma (NASDAQ:NGEN) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other research firms have also recently commented on NGEN. Weiss Ratings started coverage on NervGen Pharma in a report on Friday, April 24th. They issued a “sell (d-)” rating for the company. Wall Street Zen cut NervGen Pharma from a “sell” rating to a “strong sell” rating in a report on Monday. Stifel Nicolaus upgraded NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. Finally, HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, NervGen Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

NervGen Pharma Stock Performance

NGEN opened at $3.63 on Wednesday. NervGen Pharma has a 12 month low of $1.50 and a 12 month high of $6.30.

Key NervGen Pharma News

Here are the key news stories impacting NervGen Pharma this week:

• Positive Sentiment: HC Wainwright upgraded NGEN to a “Strong-Buy”, signalling analyst conviction in the company’s longer‑term prospects. Zacks: HC Wainwright Upgrade
• Neutral Sentiment: HC Wainwright published a full set of quarterly and annual EPS projections (Q1–Q4 2026: roughly ($0.07)–($0.10) per quarter; FY2026: ($0.36) EPS; Q1–Q4 2027: roughly ($0.11)–($0.13) per quarter; FY2027: ($0.49) EPS). The firm’s coverage provides a clearer near‑term earnings trajectory but does not change published clinical or corporate milestones. MarketBeat: NGEN Coverage
• Negative Sentiment: Despite the upgrade, the EPS outlook shows continued negative earnings (ongoing losses and implied cash burn through FY2027), which can weigh on valuation and may explain downward pressure on the share price today. MarketBeat: NGEN Coverage

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.